Schmid J P, Regamey C
Clinique de médecine, Hôpital cantonal, Fribourg.
Schweiz Med Wochenschr. 1994 Dec 10;124(49):2229-33.
New oral antibiotics with high rates of absorption and good bioavailability make it possible to reduce costs by shortening the i.v. treatment period. During two 2-month periods we analyzed every patient of the Medical Department who received i.v. treatment. We tried to reduce i.v. treatment duration simply by discussion with the responsible physician, guided essentially by the clinical course. The number of patients with reduced i.v. treatment were compared with a control period. We found that by this means, an i.v. treatment period of 4-7 days could often be reduced to 1-3 days. The main target pathologies with corresponding cost savings appeared to be infections of the lower respiratory tract, with a cost-saving potential of 1.4 days (p < 0.0001) and urinary tract infections with a cost-saving potential of SFr. 179.-(US$ 138.-) per case.
吸收速率高且生物利用度良好的新型口服抗生素，使得通过缩短静脉治疗周期来降低成本成为可能。在两个为期2个月的时间段内，我们分析了内科接受静脉治疗的每一位患者。我们主要根据临床病程，通过与负责医生讨论，试图缩短静脉治疗时长。将静脉治疗时长缩短的患者数量与一个对照期进行比较。我们发现，通过这种方式，静脉治疗周期通常可以从4 - 7天缩短至1 - 3天。主要的目标病症及相应的成本节省情况似乎是下呼吸道感染，成本节省潜力为1.4天（p < 0.0001），以及尿路感染，每例成本节省潜力为179瑞士法郎（138美元）。
